Loading...

Mark Moasser, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address1450 Third St
San Francisco CA 94158
Phone415-353-7070
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Tufts University, Boston, MAM.D.1988School of Medicine
    University of Pennsylvania, Philadelphia, PAB.A.1984Biophysics, Music
    New York Hospital - Cornell Medical Center, New York, NYResidency1991Internal Medicine
    Memorial Sloan-Kettering Cancer Center, New York, NYFellowship1995Medical Oncology

    Collapse Overview 
    Collapse Overview
    Physician-scientist seeking to understand the molecular basis of cancers, particularly oncogene-driven cancers, and to translate this knowledge into highly effective treatments for cancer.

    Collapse Research 
    Collapse Research Activities and Funding
    Development of first-in-class HER3 inhibitors
    UCSF Clinical and Translational Sciences Institute Catalyst 000000Apr 10, 2017 - Oct 9, 2018
    Role: PI, with coPI Jack Taunton
    A next-generation approach for inactivation of the HER2-HER3 tumor driver
    BCRF-AACR 218084Sep 1, 2012 - Aug 31, 2014
    Role: Principal Investigator
    Role Description: with David Agard
    Understanding the adaptational network underlying HER3 addiction
    California Breast Cancer Research Program 18IB-0030Aug 1, 2012 - Jul 31, 2013
    Role: Principal Investgator
    Towards highly effective inactivation of HER2-HER3 signaling
    California Breast Cancer Research Program 16OB-0150Jul 1, 2010 - Jun 30, 2014
    Role: Principal Investigator
    Breaking the HER3 barrier in the treatment of HER2-amplified breast cancer
    Mary Kay Ash Charitable Foundation Mary Kay Ash Charitable FoundationDec 1, 2009 - Nov 30, 2011
    Role: Principle Investigator
    An integrated approach towards the eradication of HER2-driven breast cancer
    Susan G. Komen Foundation KG081684Jan 22, 2008 - Jan 21, 2010
    Role: Principal Investigator
    Role Description: with John Kuriyan & Jim Wells
    Pilot studies to develop probes for in vivo imaging of P13K/Akt pathway activity
    NIH/NCI R21CA121108Jan 1, 2007 - Dec 31, 2009
    Role: Principal Investigator
    Understanding resistance in the HER2-HER3 tumor drive
    NIH/NCI R01CA122216Jul 1, 2006 - May 31, 2018
    Role: PI
    Anatomic and Biologic Staging of Breast Disease with MRI
    NIH/NCI R01 CA069587Apr 1, 2006 - Nov 30, 2011
    Role: co-investigator
    HER3 infidelity and resistance to tyrosine kinase inhibitors
    California Breast Cancer Research Program 11IB-0069Aug 1, 2005 - Jun 30, 2007
    Role: Principal Investigator
    Promiscuous HER3 signaling; A new target in the treatment of breast cancer
    Susan G. Komen Foundation BCTR0504177May 1, 2005 - Apr 30, 2008
    Role: Principal Investigator
    Adhesion signaling by a novel mitotic substrate of src
    NIH/NCI R01CA113952Apr 1, 2005 - Mar 31, 2010
    Role: Principal Investigator
    Model-based predictions of responses to RTK pathway therapies
    National Institutes of Health U54 CA112970Sep 30, 2004 - Feb 28, 2015
    Role: PI on sub-project
    Model-based predictions of responses to RTK pathway therapies
    NIH/NCI U54 CA112970Sep 30, 2004 - Feb 28, 2015
    Role: Co-investigator
    A novel mitotic phosphoprotein associated with src kinases
    American Cancer Society RSG-02-139-01-CDDJul 1, 2002 - Jun 30, 2006
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. Nat Cell Biol. 2019 06; 21(6):778-790. Coppé JP, Mori M, Pan B, Yau C, Wolf DM, Ruiz-Saenz A, Brunen D, Prahallad A, Cornelissen-Steijger P, Kemper K, Posch C, Wang C, Dreyer CA, Krijgsman O, Lee PRE, Chen Z, Peeper DS, Moasser MM, Bernards R, van 't Veer LJ. PMID: 31160710.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    2. A Dimerization Function in the Intrinsically Disordered N-Terminal Region of Src. Cell Rep. 2018 10 09; 25(2):449-463.e4. Spassov DS, Ruiz-Saenz A, Piple A, Moasser MM. PMID: 30304684.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    3. HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3. Cancer Res. 2018 07 01; 78(13):3645-3658. Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia N, Moasser MM. PMID: 29760043.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    4. Regulation of inside-out ß1-integrin activation by CDCP1. Oncogene. 2018 05; 37(21):2817-2836. Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser MM, Carter WG, Satapathy SR, Shah K, Knudsen BS. PMID: 29511352.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    5. Targeting HER2 by Combination Therapies. J Clin Oncol. 2018 03 10; 36(8):808-811. Ruiz-Saenz A, Moasser MM. PMID: 29381433.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. PMID: 28790114.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    7. CD318 is a ligand for CD6. Proc Natl Acad Sci U S A. 2017 08 15; 114(33):E6912-E6921. Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F. PMID: 28760953.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    8. Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase. Cell Chem Biol. 2017 07 20; 24(7):917. Littlefield P, Moasser MM, Jura N. PMID: 28732202.
      View in: PubMed   Mentions:    Fields:    
    9. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. PMID: 26875185.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    10. Effective treatment of HER2-amplified breast cancer by targeting HER3 and ß1 integrin. Breast Cancer Res Treat. 2016 Feb; 155(3):431-40. Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser MM, Park CC. PMID: 26860947.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    11. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Oncotarget. 2015 Dec 01; 6(38):41123-33. Amin DN, Ruiz-Saenz A, Gulizia N, Moasser MM. PMID: 26516700.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    12. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncol. 2015 Nov; 1(8):1154-61. Moasser MM, Krop IE. PMID: 26204261.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCells
    13. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Mol Cancer Ther. 2015 Dec; 14(12):2805-17. Amin DN, Ahuja D, Yaswen P, Moasser MM. PMID: 26438156.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    14. Disentangling multidimensional spatio-temporal data into their common and aberrant responses. PLoS One. 2015; 10(4):e0121607. Chang YH, Korkola J, Amin DN, Moasser MM, Carmena JM, Gray JW, Tomlin CJ. PMID: 25901353.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum. Oncogene. 2015 Oct 08; 34(41):5288-94. Ruiz-Saenz A, Sandhu M, Carrasco Y, Maglathlin RL, Taunton J, Moasser MM. PMID: 25619841.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    16. HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive. Clin Cancer Res. 2015 Jul 01; 21(13):2886-8. Campbell MR, Moasser MM. PMID: 25609069.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    17. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. PMID: 25605863.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    18. A multilevel model of postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2078-92. Hiatt RA, Porco TC, Liu F, Balke K, Balmain A, Barlow J, Braithwaite D, Diez-Roux AV, Kushi LH, Moasser MM, Werb Z, Windham GC, Rehkopf DH. PMID: 25017248.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    19. Two dimensions in targeting HER2. J Clin Oncol. 2014 Jul 01; 32(19):2074-7. Moasser MM. PMID: 24868026.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    20. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser MM. PMID: 24711549.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    21. RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chem Biol. 2014 04 24; 21(4):453-458. Littlefield P, Moasser MM, Jura N. PMID: 24656791.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    22. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013 Feb 01; 73(3):1168-79. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser MM. PMID: 23243018.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    23. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J. 2012 Nov 01; 447(3):417-25. Amin DN, Sergina N, Lim L, Goga A, Moasser MM. PMID: 22853430.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    24. A tumor-suppressing function in the epithelial adhesion protein Trask. Oncogene. 2012 Jan 26; 31(4):419-31. Spassov DS, Wong CH, Harris G, McDonough S, Phojanakong P, Wang D, Hann B, Bazarov AV, Yaswen P, Khanafshar E, Moasser MM. PMID: 21706059.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    25. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011 Jun 07; 104(12):1828-35. Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. PMID: 21559012.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCellsCTClinical Trials
    26. The structural features of Trask that mediate its anti-adhesive functions. PLoS One. 2011 Apr 29; 6(4):e19154. Spassov DS, Ahuja D, Wong CH, Moasser MM. PMID: 21559459.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    27. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell Cycle. 2011 Apr 15; 10(8):1225-32. Spassov DS, Wong CH, Moasser MM. PMID: 21490433.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    28. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. PMID: 21350003.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    29. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011 Feb; 31(4):766-82. Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser MM. PMID: 21189288.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    30. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010 Dec; 21(9):944-50. Amin DN, Campbell MR, Moasser MM. PMID: 20816829.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    31. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010 Mar 01; 16(5):1373-83. Campbell MR, Amin D, Moasser MM. PMID: 20179223.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansAnimalsCells
    32. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010 Jan 27; 2(16):16ra7. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser MM. PMID: 20371474.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsCells
    33. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. PMID: 19706807.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    34. MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model. J Magn Reson Imaging. 2009 May; 29(5):1071-9. Aliu SO, Wilmes LJ, Moasser MM, Hann BC, Li KL, Wang D, Hylton NM. PMID: 19388114.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    35. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009 May; 174(5):1756-65. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser MM. PMID: 19349359.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    36. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009 Apr 01; 15(7):2311-22. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser MM. PMID: 19318475.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    37. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7878-83. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser MM, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. PMID: 19047117.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCTClinical Trials
    38. HER-2-directed, small-molecule antagonists. Curr Opin Investig Drugs. 2008 Dec; 9(12):1264-76. Arkin M, Moasser MM. PMID: 19037833.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    39. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008 Oct 01; 415(1):97-110. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D. PMID: 18498248.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCells
    40. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 2008 May; 65(10):1566-84. Wieduwilt MJ, Moasser MM. PMID: 18259690.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansAnimalsCells
    41. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. Chien AJ, Moasser MM. PMID: 18410794.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    42. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging. 2007 Dec; 26(6):1618-25. Moasser MM, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. PMID: 17968965.
      View in: PubMed   Mentions: 13     Fields:    Translation:Animals
    43. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007 Dec; 13(12):527-34. Sergina NV, Moasser MM. PMID: 17981505.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    44. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer. Breast Cancer Res Treat. 2008 Sep; 111(2):377-88. Traina TA, Poggesi I, Robson M, Asnis A, Duncan BA, Heerdt A, Dang C, Lake D, Moasser M, Panageas K, Borgen P, Norton L, Hudis C, Dickler MN. PMID: 17952589.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    45. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer. 2007 Aug 20; 97(4):453-7. Hsieh AC, Moasser MM. PMID: 17667926.
      View in: PubMed   Mentions: 98     Fields:    Translation:Humans
    46. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene. 2007 Oct 11; 26(46):6577-92. Moasser MM. PMID: 17486079.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCells
    47. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007 Oct 04; 26(45):6469-87. Moasser MM. PMID: 17471238.
      View in: PubMed   Mentions: 190     Fields:    Translation:HumansAnimalsCells
    48. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007 Jan 25; 445(7126):437-41. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM. PMID: 17206155.
      View in: PubMed   Mentions: 338     Fields:    Translation:Cells
    49. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc. 2006 Jul; 54(7):1119-24. Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C. PMID: 16866685.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    50. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006 Jun; 54(6):925-31. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J. PMID: 16776787.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    51. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat. 2006 Aug; 98(3):343-8. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. PMID: 16541322.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    52. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene. 2005 Aug 11; 24(34):5333-43. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser MM. PMID: 16007225.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    53. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer. 2005 Apr; 6(1):55-60. Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser MM, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. PMID: 15899073.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    54. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2005 Mar; 90(2):157-63. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA. PMID: 15803362.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    55. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4062-7. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. PMID: 15217939.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    56. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell Cycle. 2004 Jun; 3(6):796-803. Mizenina OA, Moasser MM. PMID: 15136770.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    57. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res. 2003 Oct 01; 9(12):4340-6. She QB, Solit D, Basso A, Moasser MM. PMID: 14555504.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCells
    58. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res. 2003 Apr; 9(4):1267-73. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser MM. PMID: 12684394.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    59. The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer. Breast Cancer Res Treat. 2002 May; 73(2):135-44. Moasser MM, Rosen N. PMID: 12088116.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    60. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res. 2001 Dec; 7(12):3934-41. Fornier MN, Seidman AD, Theodoulou M, Moynahan ME, Currie V, Moasser M, Sklarin N, Gilewski T, D'Andrea G, Salvaggio R, Panageas KS, Norton L, Hudis C. PMID: 11751485.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    61. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001 Oct 01; 61(19):7184-8. Moasser MM, Basso A, Averbuch SD, Rosen N. PMID: 11585753.
      View in: PubMed   Mentions: 102     Fields:    Translation:HumansCells
    62. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001 May 15; 19(10):2587-95. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA. PMID: 11352950.
      View in: PubMed   Mentions: 107     Fields:    Translation:HumansCTClinical Trials
    63. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 2001 Apr 01; 61(7):2945-52. Münster PN, Srethapakdi M, Moasser MM, Rosen N. PMID: 11306472.
      View in: PubMed   Mentions: 40     Fields:    Translation:Cells
    64. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: a phase I/II clinical trial. Breast Cancer Res Treat. 2001 Apr; 66(3):239-48. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, Bloch R, Ligueros M, Sonenberg M, Norton L, Hudis C. PMID: 11510695.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    65. Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate Cancer Prostatic Dis. 2001; 4(1):33-43. Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI. PMID: 12497061.
      View in: PubMed   Mentions: 5     Fields:    
    66. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res. 1999 Dec 15; 59(24):6145-52. Moasser MM, Srethapakdi M, Sachar KS, Kraker AJ, Rosen N. PMID: 10626805.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    67. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci U S A. 1998 Feb 17; 95(4):1369-74. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su DS, Danishefsky SJ, Rosen N. PMID: 9465021.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    68. Derivation and characterization of retinoid-resistant human embryonal carcinoma cells. Differentiation. 1996 Jul; 60(4):251-7. Moasser MM, Khoo KS, Maerz WJ, Zelenetz A, Dmitrovsky E. PMID: 8765055.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    69. Transfection with a CRIPTO anti-sense plasmid suppresses endogenous CRIPTO expression and inhibits transformation in a human embryonal carcinoma cell line. Int J Cancer. 1996 May 16; 66(4):538-43. Baldassarre G, Bianco C, Tortora G, Ruggiero A, Moasser M, Dmitrovsky E, Bianco AR, Ciardiello F. PMID: 8635871.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    70. Growth suppression of transformed human bronchial epithelial cells by all-trans-retinoic acid occurs through specific retinoid receptors. Oncogene. 1995 Dec 07; 11(11):2357-64. Ahn MJ, Langenfeld J, Moasser MM, Rusch V, Dmitrovsky E. PMID: 8570187.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    71. all-trans retinoic acid for treating germ cell tumors. In vitro activity and results of a phase II trial. Cancer. 1995 Aug 15; 76(4):680-6. Moasser MM, Motzer RJ, Khoo KS, Lyn P, Murphy BA, Bosl GJ, Dmitrovsky E. PMID: 8625166.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    72. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR alpha or PML. Oncogene. 1995 Jun 15; 10(12):2307-14. Ahn MJ, Nason-Burchenal K, Moasser MM, Dmitrovsky E. PMID: 7784078.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    73. Overexpression of the retinoic acid receptor gamma directly induces terminal differentiation of human embryonal carcinoma cells. Oncogene. 1995 Apr 20; 10(8):1537-43. Moasser MM, Reuter VE, Dmitrovsky E. PMID: 7731708.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    74. Response and resistance to retinoic acid are mediated through the retinoic acid nuclear receptor gamma in human teratocarcinomas. Oncogene. 1994 Mar; 9(3):833-40. Moasser MM, DeBlasio A, Dmitrovsky E. PMID: 8108126.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    Mark's Networks
    Concepts (403)
    Derived automatically from this person's publications.
    _
    Co-Authors (49)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _